SUNNYVALE, Calif., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC), a life sciences and molecular diagnostics leader, is showcasing its high sensitivity, high specificity patented and proprietary microarray platform at the 21 st International Molecular Medicine Tri-Conference in San Francisco, CA, USA on February 9-14, 2014. The conference, which features more than 3,000 researchers and clinicians from 35 countries, focuses on drug discovery, genomics, diagnostics and information technology. Arrayit microarray technology utilizes ex situ synthesis, high-speed mechanical micro-spotting, advanced coupling and surface chemistry, high-sensitivity fluorescence labeling and detection, and proprietary data analysis and mining bioinformatics to identify blood stream biomarkers with greater sensitivity and specificity than competing microarray and next-generation sequencing platforms. On FDA approval, Arrayit's OvaDx® Pre-Symptomatic Ovarian Cancer Test will uniquely enable monitoring and screening of ovarian cancer as early as five years before patients report symptoms of the illness. Arrayit offers its platform on a royalty-free basis to research laboratories, which provides the company with a rich discovery pipeline and numerous commercialization opportunities as researchers decipher diagnostic pathways, drug targets, and high-value genomic and proteomic biomarkers. Arrayit also offers affordable royalty agreements to empower molecular diagnostics companies wishing to use ARYC technology for manufacturing. The company is conducting personalized meetings with customers, investors, investment bankers, and the life sciences media at conference booth 8 for the duration of the conference, which is sponsored by Bio-Rad, IBM, Illumina, Life Technologies, NanoString, Philips, and other molecular medicine leaders. About Arrayit Corporation Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life™ Visit www.arrayit.com or more information. Safe Harbor Statement We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and in Form 10-Q for the quarterly period ended September 30, 2013.
CONTACT: Investor Relations Arrayit Corporation 408.744.1331 email@example.com